A PCAC recommendation is not a green light
When a peptide gets a favorable committee vote, the marketing gets loud fast. Here is what a vote actually means — and how bulk-substance provisions, interim policy and final-list rulemaking differ. The topics below are not a mandatory three-step sequence. Monitoring, not legal advice.
- 1
Bulk-substance provisions and interim nomination policy
Assess the exact substance, form and route under the applicable monograph, approved-drug-component and final-list provisions. Category 1 nominations are under FDA evaluation. FDA’s January 2025 interim policy describes conditional enforcement discretion; Category 1 is not final approval, and Category 2 is outside that policy.
- 2
PCAC recommendation (a vote, not a rule)
The Pharmacy Compounding Advisory Committee reviews the evidence and votes a recommendation to FDA. FDA is not bound by it, and the recommendation itself changes nothing about what may be compounded. This is a milestone, not a green light.
- 3
Final 503A Bulks List through rulemaking
FDA establishes the final list through proposed and final regulations. This process is distinct from Category 1 nomination status and advisory votes. No fixed completion period is established here. Final-list inclusion does not remove the other applicable 503A conditions.
Assess the applicable provision and conditions. A nomination tag or advisory vote alone establishes neither permission nor prohibition. MedSpaRadar sells no substance; we report dated records and citations.
Published peptide review records
Published tracker records, newest source-event date first. Review tags do not establish current eligibility; primary vote-tally verification is not established here.
- PCAC 07/23/2026 ↗
MedSpaRadar qualification: FDA is not bound by PCAC recommendations. A reported recommendation does not establish current compounding eligibility. Category 1 nomination and FDA’s conditional interim enforcement policy are distinct from final 503A Bulks List rulemaking. The former explanation incorrectly tied Category 1 placement to rulemaking and supplied an unsupported 8–12 month estimate; it has been superseded. Assess the exact substance, form, route and all applicable conditions; no individual eligibility determination is made here.
Superseded editorial explanation — archival evidence only
Superseded editorial explanation, retained as historical evidence only. Its original author is not established; MSR analysis marks our qualification and archival presentation, not verified authorship. This is not an FDA quotation or current guidance. Recommendation, staff-position and vote-tally claims remain reported; primary verification is not established here.
Under PCAC review — not yet compoundable. On Jul 23, 2026 the Pharmacy Compounding Advisory Committee recommended adding BPC-157 to the FDA 503A Bulks List, 8–6–1 (FDA meeting minutes pending; FDA staff had recommended against). A recommendation is not a legal change — FDA is not bound, and 503A compounding would require Category 1 placement via notice-and-comment rulemaking (commonly 8–12 months).
Original text SHA256: 49d24f41cf3ef18f7eb9aaaded0a19e08c9db8488f976e2a9ce3eb4385c81243
- PCAC 07/23/2026 ↗
MedSpaRadar qualification: FDA is not bound by PCAC recommendations. A reported recommendation does not establish current compounding eligibility. Category 1 nomination and FDA’s conditional interim enforcement policy are distinct from final 503A Bulks List rulemaking. The former explanation incorrectly tied Category 1 placement to rulemaking and supplied an unsupported 8–12 month estimate; it has been superseded. Assess the exact substance, form, route and all applicable conditions; no individual eligibility determination is made here.
Superseded editorial explanation — archival evidence only
Superseded editorial explanation, retained as historical evidence only. Its original author is not established; MSR analysis marks our qualification and archival presentation, not verified authorship. This is not an FDA quotation or current guidance. Recommendation, staff-position and vote-tally claims remain reported; primary verification is not established here.
Under PCAC review — not yet compoundable. On Jul 23, 2026 the Pharmacy Compounding Advisory Committee recommended adding KPV to the FDA 503A Bulks List, 8–6–1 (FDA meeting minutes pending; FDA staff had recommended against). A recommendation is not a legal change — FDA is not bound, and 503A compounding would require Category 1 placement via notice-and-comment rulemaking (commonly 8–12 months).
Original text SHA256: bb816031172167409507ffa626af42a1a8c8ef271646307a04ca65cbff8f5daf
- PCAC 07/23/2026 ↗
MedSpaRadar qualification: FDA is not bound by PCAC recommendations. A reported recommendation does not establish current compounding eligibility. Category 1 nomination and FDA’s conditional interim enforcement policy are distinct from final 503A Bulks List rulemaking. The former explanation incorrectly tied Category 1 placement to rulemaking and supplied an unsupported 8–12 month estimate; it has been superseded. Assess the exact substance, form, route and all applicable conditions; no individual eligibility determination is made here.
Superseded editorial explanation — archival evidence only
Superseded editorial explanation, retained as historical evidence only. Its original author is not established; MSR analysis marks our qualification and archival presentation, not verified authorship. This is not an FDA quotation or current guidance. Recommendation, staff-position and vote-tally claims remain reported; primary verification is not established here.
Under PCAC review — not yet compoundable. On Jul 23, 2026 the Pharmacy Compounding Advisory Committee recommended adding MOTS-c to the FDA 503A Bulks List, 7–5–2 (FDA meeting minutes pending; FDA staff had recommended against). A recommendation is not a legal change — FDA is not bound, and 503A compounding would require Category 1 placement via notice-and-comment rulemaking (commonly 8–12 months).
Original text SHA256: a8c81d9a5aa318865ce0744aa6dec3e2be891cb9d9c5713838ce526382a88600
- PCAC 07/23/2026 ↗
MedSpaRadar qualification: FDA is not bound by PCAC recommendations. A reported recommendation does not establish current compounding eligibility. Category 1 nomination and FDA’s conditional interim enforcement policy are distinct from final 503A Bulks List rulemaking. The former explanation incorrectly tied Category 1 placement to rulemaking and supplied an unsupported 8–12 month estimate; it has been superseded. Assess the exact substance, form, route and all applicable conditions; no individual eligibility determination is made here.
Superseded editorial explanation — archival evidence only
Superseded editorial explanation, retained as historical evidence only. Its original author is not established; MSR analysis marks our qualification and archival presentation, not verified authorship. This is not an FDA quotation or current guidance. Recommendation, staff-position and vote-tally claims remain reported; primary verification is not established here.
Under PCAC review — not yet compoundable. On Jul 23, 2026 the Pharmacy Compounding Advisory Committee recommended adding TB-500 to the FDA 503A Bulks List, 8–6–1 (FDA meeting minutes pending; FDA staff had recommended against). A recommendation is not a legal change — FDA is not bound, and 503A compounding would require Category 1 placement via notice-and-comment rulemaking (commonly 8–12 months).
Original text SHA256: da4091be12c4065930023f6b5d11b247f8d8ff307dfca15a4c7fc07613b7b5b2
Stored event summary — not a current eligibility determination: Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List
2026-07361 ↗Stored event summary — not a current eligibility determination: Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List
2026-07361 ↗Stored event summary — not a current eligibility determination: Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List
2026-07361 ↗Stored event summary — not a current eligibility determination: Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List
2024-24828 ↗
Sources
Track the standing, not the hype
We watch the Federal Register and FDA and tell you when a peptide’s legal standing actually changes — with the citation.
Get the free Brief →Get regulatory changes as they publish
We scan all 50 state legislatures daily, plus the FDA and the Federal Register. Free weekly Brief — what changed, in plain language, with the source.
Free · unsubscribe in one click · we never sell your address